Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells $97,715.48 in Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) insider Francesca Barone sold 13,534 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total transaction of $97,715.48. Following the completion of the sale, the insider now directly owns 110,673 shares in the company, valued at $799,059.06. This represents a 10.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Francesca Barone also recently made the following trade(s):

• On Wednesday, January 8th, Francesca Barone sold 13,673 shares of Candel Therapeutics stock. The stock was sold at an average price of $8.22, for a total transaction of $112,392.06.

Candel Therapeutics Price Performance

Candel Therapeutics stock opened at $6.66 on Monday. The company has a market cap of $216.32 million, a PE ratio of -3.85 and a beta of -1.20. Candel Therapeutics, Inc. has a 12 month low of $1.16 and a 12 month high of $14.60. The company has a fifty day moving average price of $6.61 and a two-hundred day moving average price of $6.28.

Institutional Investors Weigh In On Candel Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Point72 DIFC Ltd acquired a new position in Candel Therapeutics in the second quarter valued at approximately $31,000. FMR LLC bought a new stake in shares of Candel Therapeutics in the 3rd quarter worth approximately $46,000. MetLife Investment Management LLC bought a new stake in shares of Candel Therapeutics in the 3rd quarter worth approximately $87,000. Atom Investors LP acquired a new position in Candel Therapeutics during the 3rd quarter valued at approximately $103,000. Finally, Rhumbline Advisers acquired a new stake in Candel Therapeutics in the second quarter worth $143,000. Institutional investors and hedge funds own 13.93% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $19.00 price target (up previously from $11.00) on shares of Candel Therapeutics in a research report on Wednesday, December 18th.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.